What is Ingersoll Rand's biopharma — goodwill?

Ingersoll Rand (IR) reported biopharma — goodwill of $816.60M in Q2 2025.

What does biopharma — goodwill mean?

The portion of the biopharma segment's purchase price that represents intangible value like brand and market position rather than physical assets.

Discontinued — last reported Q2 '25

Business Segments · Goodwill

Biopharma — Goodwill

Analysis

StatementSegment

CategoryCapital Allocation

SignalContext dependent

VolatilityStable

First reportedQ2 2025

Last reportedQ2 2025

Rolls up toGoodwill

How to read this metric

A high or growing balance suggests significant historical acquisition activity, while a sudden decrease typically signals an impairment event reflecting reduced expectations for the segment.

Detailed definition

This metric represents the intangible asset value recorded on the balance sheet when the purchase price of a biopharma-r...

Peer comparison

Companies with active M&A strategies in the life sciences and industrial technology spaces often carry significant goodwill balances, which are evaluated against the segment's return on invested capital.

Metric ID: ir_segment_biopharma_goodwill

Historical Data

1 periods

	Q2 '25
Value	$816.60M

Similar Metrics at Other Companies

PfizerPFE View metric

WAT

Waters CorporationWAT View metric

GLW

CorningGLW View metric

Agilent TechnologiesA View metric

PfizerPFE View metric

Frequently Asked Questions

What is Ingersoll Rand's biopharma — goodwill?: Ingersoll Rand (IR) reported biopharma — goodwill of $816.60M in Q2 2025.
What does biopharma — goodwill mean?: The portion of the biopharma segment's purchase price that represents intangible value like brand and market position rather than physical assets.